CASPR

Center for Addiction, Science, Policy, and Research, Advancing breakthroughs and innovation for substance use disorders.
Subscribe to our substack!

[CASPR @CASPR_Research]

Innovation policy to create new breakthrough treatments for addiction is a smarter path. Unlike everything else that politicians have tried, it can actually be effective. Many of these recommendations would be of great impact at no cost to the government.

[Nicholas Reville @nreville]

An Innovation Agenda for Addiction: new policy paper by me and @willyintheworld for @CASPR_Research and @IFP.  We can’t solve addiction without dramatically better medicines– and a massive market failure is holding us back.

https://t.co/chm3PNuMck

[Naval @naval]

https://t.co/4w2chXLeLk

[CASPR @CASPR_Research]

CASPR, and our research on GLP-1s for opioid use disorder, got a shout-out in this fascinating convo between @naval and @ChrisWillx .

They discussed the ideas that will shape the future, and call out GLP-1s to treat addiction.

5:30 for Naval's shout-out!

https://t.co/NOgN8iO5k2

[Cato Institute @CatoInstitute]

Tune in to our policy forum "The Harm Reduction Promise of GLP-1s" with @mfcannon, @dr4liberty, @slsatel and @nreville.
https://t.co/ilTap3ugRQ

[CASPR @CASPR_Research]

*starting in 10 minutes*

join the livestream to hear @nreville speak about the transformative implications of GLP-1s for addiction treatment, and policies to improve affordability and access for those who need them.

[CASPR @CASPR_Research]

Please join us in person or online at this free @CatoInstitute event on Jan 24th. @nreville will be speaking about GLP-1s and innovation in addiction medicine, moderated by Dr. Jeffrey Singer, @dr4liberty.

Register free here:
https://t.co/OA3KGNhND6

[CASPR @CASPR_Research]

GLP-1s and addiction, "cravings are a more specific and more helpful way to look at what’s happening in addiction. And if you reduce those cravings, you can give people a chance, some space in their lives to address the other patterns, the other circumstances that have led them in that direction"

[Chris Hayes @chrislhayes]

This conversation with my friend @nreville about his quest to find a medical cure for addiction is one of the most hopeful, best conversations we've had on #WITHPod

https://t.co/BFk6E8kNfd

[CASPR @CASPR_Research]

Please join us in person or online at this free @CatoInstitute event on Jan 24th. @nreville will be speaking about GLP-1s and innovation in addiction medicine, moderated by Dr. Jeffrey Singer, @dr4liberty.

Register free here:
https://t.co/OA3KGNhND6

[CASPR @CASPR_Research]

CASPR Executive Director @nreville is on the @chrislhayes podcast today, hope you will listen!

iOS:
https://t.co/fodWT9kOtr

Spotify:
https://t.co/F5euKuL1Do

[Jennifer Doleac @jenniferdoleac]

It's very cool to see what @CASPR_Research is doing to spur innovation in the treatment of substance use disorders (e.g. GLP-1s). Check out some of their recent activities:

https://t.co/opJ3ufFt6V

[CASPR @CASPR_Research]

"The Harm Reduction Promise of GLP-1s"

CASPR Cofounder @nreville will be speaking at this event at @CatoInstitute on January 24. Please join us, in person or online. Registration is open.

https://t.co/OA3KGNhfNy

[Chris Hayes @chrislhayes]

https://t.co/vAHOLr2YNt

[CASPR @CASPR_Research]

Addiction can be cured if we can get pharmaceutical companies to focus on the problem. Our publication with Federation of American Scientists proposes realistic policy interventions that can work.

If nothing else, take a look at the first two charts. It will change how you understand the issue.

Written by CASPR Cofounder @nreville and @Willyintheworld from @IFP

https://t.co/6pYtum9UVa

[CASPR @CASPR_Research]

@elonmusk We know how to make GLP-1s cheap and widely available, at scale. Traditional pharma can't / won't.

[CASPR @CASPR_Research]

Our addiction predictions for 2025 and beyond: GLP-1 micro-dosing, non-opioid painkillers, alcohol trends, and more.

https://t.co/VOJEU64ExA

[CASPR @CASPR_Research]

@elonmusk We know how to get GLP-1s cheap *at scale* and get them approved for treating addictions, inc opioids, alcohol, and smoking.  
Can we pitch someone on your team?

[Paul Niehaus @PaulFNiehaus]

An innovation agenda for addiction, from @CASPR_Research @IFP
https://t.co/5WZ7gYfj83

[Anand Muthusamy @mu_anand]

Excellent call to action re: addiction & biotech.
Yes, drugs meant to affect behavior are challenging on all levels...all the more reasons to improve how they are designed and distributed today. ~750k deaths/year in the U.S. is staggering.

[Derek Thompson @DKThomp]

@Willyintheworld @nreville @CASPR_Research omfg I was just thinking to myself that I wanted to read something like this